Takayuki Kishiro's Contact Details

Takayuki Kishiro's Company Details

Vitrolife is committed to supporting successful treatment outcomes, through a focus on IVF and the needs of clinics and testing labs. We've been dedicated to IVF since 1994, when the field was still young. Today, we support customers worldwide - always with sustainability in mind. Vitrolife Group has approximately 1200 employees and the headquarter is located in Sweden with additional locations and production facilities in more than 20 countries world-wide.In 2021, Vitrolife acquired Igenomix which is a leader in women's health and reproductive genetic testing services for IVF clinics, founded in 2011. Together we create a global leader in reproductive health and by combining Igenomix's portfolio of reproductive genetic testing services with Vitrolife's best-in-class IVF device portfolio, we will be able to better support clinics and patients across the fertility journey.Vitrolife was one of the first companies to provide IVF laboratories with high-quality, ready-to-use culture media. Today, our portfolio includes product solutions ranging from oocyte retrieval all the way to embryo transfer and cryopreservation. Demand is growing for innovative methods for embryo evaluation and selection. Vitrolife offers time-lapse systems and software, as well as leading product solutions for preimplantation genetic testing. These solutions help clinics to evaluate and select the most viable embryos, and improve IVF outcomes. Vitrolife's vision is to fulfil the dream of having a baby, and we achieve this by supporting our customers in delivering successful treatment outcomes. We're your committed partner for the IVF journey. We can help you maximise success. – Together. All the way. The Vitrolife share is listed on NASDAQ OMX Stockholm, Nordic Large Cap.